share_log

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49

Benzinga ·  Nov 6 07:27  · Ratings

Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $45 to $49.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment